Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 56

Results For "ASH"

2702 News Found

Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial
Clinical Trials | November 07, 2025

Valneva’s next-gen Zika vaccine shows strong safety and immune response in phase I trial

VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus


UPS acquires Andlauer for $1.6 billion to strengthen global healthcare network
Supply Chain | November 07, 2025

UPS acquires Andlauer for $1.6 billion to strengthen global healthcare network

The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings


Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025
Clinical Trials | November 06, 2025

Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025

Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively


EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform
News | November 06, 2025

EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform

Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible


Cupid bags largest share in South Africa’s 5-year National Condom Program
News | November 06, 2025

Cupid bags largest share in South Africa’s 5-year National Condom Program

Cupid has been allocated approximately 23.4 million units of female condoms per year


J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial
News | November 06, 2025

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year


Teva reports 11th consecutive quarter of growth
News | November 06, 2025

Teva reports 11th consecutive quarter of growth

Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.


IPP organises webinar on
News | November 05, 2025

IPP organises webinar on "Transforming Formulation R&D: Data, Digitalization and Beyond" on November 6, 2025

Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post


Kulzer reshapes global strategy to drive growth in EMEA and Americas
News | November 04, 2025

Kulzer reshapes global strategy to drive growth in EMEA and Americas

Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany


Roche’s Gazyva shows breakthrough efficacy in phase III lupus study
Clinical Trials | November 04, 2025

Roche’s Gazyva shows breakthrough efficacy in phase III lupus study

The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response